1. Generics Bulletin
  2. >>Business
  3. >>Deals

Mylan Bids To Win EU Approval For Upjohn Merger

New Zealand Watchdog Also Raises Potential Concerns

 
• By Dean Rudge

Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.

Sale
Mylan may have to divest products to get its merger with Pfizer's Upjohn over the line • Source: Shutterstock

Shortly after announcing a delay in the merger to the second half of this year, Mylan has offered concessions to the European Commission’s department for competition to address antitrust concerns about its plans to join with Pfizer’s Upjohn mature brands and off-patent division.

A provisional deadline of 22 April has been set by the Commission for its decision, after Mylan put forward its concessions on 27 March

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.